Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In appropriately selected patients, PSMA-PET offers superior sensitivity and specificity compared to conventional imaging (e. g., computed tomography and bone scintigraphy) as well as choline and fluciclovine PET, with the added benefit of consolidating bone and soft tissue evaluation into a single study. Despite being a newly available imaging tool, PSMA-PET has established indications, interpretation guidelines, and reporting criteria, which will be reviewed. The prostate cancer care team, from imaging specialists to those delivering treatment, should have knowledge of physiologic PSMA radiotracer uptake, patterns of disease spread, and the strengths and limitations of PSMA-PET. In this review, current and emerging applications of PSMA-PET, including appropriateness use criteria as well as image interpretation and pitfalls, will be provided with an emphasis on clinical implications.
Abdominal radiology (New York). 2024 Feb 22 [Epub ahead of print]
Shamus Moran, Heather H Cheng, Emily Weg, Eric H Kim, Delphine L Chen, Amir Iravani, Joseph E Ippolito
Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA., Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA., Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA., Division of Urologic Surgery, Washington University School of Medicine in St. Louis, St. Louis, MO, USA., Division of Nuclear Medicine, Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA., Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, 4559 Scott Ave., Mail Stop Code: 8131, St. Louis, MO, 63110, USA. .